299 related articles for article (PubMed ID: 31353426)
21. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
22. Use of Insulin in the Inpatient Setting: Need for Continued Use.
Kumar S; Molitch ME
Curr Diab Rep; 2019 Jul; 19(9):64. PubMed ID: 31346798
[TBL] [Abstract][Full Text] [Related]
23. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
Abbatecola AM; Maggi S; Paolisso G
Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of protocol-guided scheduled basal-nutritional-correction insulin over standard care for vascular surgery patients.
Harbin M; Dossa A; de Lemos J; Drummond I; Paty B; Taylor B
Can J Diabetes; 2015 Jun; 39(3):210-5. PubMed ID: 25639852
[TBL] [Abstract][Full Text] [Related]
25. DPP4 Inhibitors in the Management of Hospitalized Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Rabizadeh S; Tavakoli Ardakani MA; Mouodi M; Bitaraf M; Shab-Bidar S; Esteghamati A; Nakhjavani M
Adv Ther; 2020 Sep; 37(9):3660-3675. PubMed ID: 32671686
[TBL] [Abstract][Full Text] [Related]
26. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents].
Katsuno T; Miyagawa J
Nihon Rinsho; 2012 May; 70 Suppl 3():693-8. PubMed ID: 22768600
[No Abstract] [Full Text] [Related]
28. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline for the Management of Hyperglycemia in Adults Hospitalized for Noncritical Illness or Undergoing Elective Surgical Procedures.
Seisa MO; Saadi S; Nayfeh T; Muthusamy K; Shah SH; Firwana M; Hasan B; Jawaid T; Abd-Rabu R; Korytkowski MT; Muniyappa R; Antinori-Lent K; Donihi AC; Drincic AT; Luger A; Torres Roldan VD; Urtecho M; Wang Z; Murad MH
J Clin Endocrinol Metab; 2022 Jul; 107(8):2139-2147. PubMed ID: 35690929
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
30. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
[TBL] [Abstract][Full Text] [Related]
31. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus.
Sesti G; Avogaro A; Belcastro S; Bonora BM; Croci M; Daniele G; Dauriz M; Dotta F; Formichi C; Frontoni S; Invitti C; Orsi E; Picconi F; Resi V; Bonora E; Purrello F
Acta Diabetol; 2019 Jun; 56(6):605-617. PubMed ID: 30603867
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Charbonnel B; Schweizer A; Dejager S
Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
34. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969
[TBL] [Abstract][Full Text] [Related]
35. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
37. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
Yasuda T; Shimomura I
Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
Frandsen CS; Madsbad S
Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
[TBL] [Abstract][Full Text] [Related]
39. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
Jódar E
Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
[TBL] [Abstract][Full Text] [Related]
40. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
